Federal Contractor Profile
Scandinavian Biopharma Holding Ab
$39M obligated·1 awards·1 agencies·1 NAICS
Federal Contracts
Showing contracts 1–8 of 8 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Dec 8, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $433K |
| May 29, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $46K |
| Mar 10, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $606K |
| Sep 18, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $20M |
| Aug 29, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $254K |
| Apr 5, 2023 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $5.2M |
| May 5, 2022 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $4.3M |
| Sep 25, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH20C0137 | 541714 | THIS AWARD IS FOR THE DELIVERY OF A CGMP MANUFACTURED PRODUCT OF QUANTITY AND QUALITY THAT IT IS SUITABLE AND APPROPRIATE FOR USE IN PIVOTAL CLINICAL STUDIES TO DEMONSTRATE EFFICACY AGAINST ETEC IN ADULTS WITH THE GOAL OF FDA LICENSURE. | $8.1M |
Get Alerted Before Scandinavian Biopharma Holding Ab's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free